Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Biocept, Inc. (BIOC)

Services-medical Laboratories

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

9955 MESA RIM ROAD
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/05/2014

Market Cap

N/A

Shares Outstanding

2,630,000

Weighted SO

2,626,026

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

IBIO --.--%

AYTU --.--%

DFFN --.--%

ONTX --.--%

ATNM --.--%

Beta

0.5950

Last Div

0.0000

Range

0.32-27.0

Chg

-0.0701

Avg Vol

2157634

Mkt Cap

N/A

Exch

NASDAQ

Country

US

Phone

858 320 8200

DCF Diff

1.9535

DCF

2.9635

Div Yield

0.0000

P/S

0.0000

EV Multiple

-0.1636

P/FV

1.5544

Div Yield %

0.0000

P/E

-0.0153

PEG

0.0000

Payout

0.0000

Current Ratio

1.8074

Quick Ratio

1.5163

Cash Ratio

1.3531

DSO

-32.3617

DIO

20.3455

Op Cycle

-12.0163

DPO

54.1684

CCC

-66.1847

Gross Margin

2.0955

Op Margin

3.5260

Pretax Margin

3.2608

Net Margin

3.2571

Eff Tax Rate

-0.0037

ROA

-1.3296

ROE

-7.6150

ROCE

-1.8496

NI/EBT

0.9989

EBT/EBIT

0.9248

EBIT/Rev

3.5260

Debt Ratio

0.5244

D/E

39.9690

LT Debt/Cap

0.9709

Total Debt/Cap

0.9756

Int Coverage

-222.4825

CF/Debt

-1.1666

Equity Multi

76.2172

Rec Turnover

-11.2788

Pay Turnover

6.7382

Inv Turnover

17.9401

FA Turnover

-0.7018

Asset Turnover

-0.4082

OCF/Share

-13.0455

FCF/Share

-13.3580

Cash/Share

6.3992

OCF/Sales

1.4986

FCF/OCF

1.0240

CF Coverage

-1.1666

ST Coverage

-7.0944

CapEx Coverage

-41.7346

Div&CapEx Cov

-41.7346

P/BV

1.5544

P/B

1.5544

P/S

0.0000

P/E

-0.0153

P/FCF

0.0000

P/OCF

-0.0333

P/CF

-0.0333

PEG

0.0000

P/S

0.0000

EV Multiple

-0.1636

P/FV

1.5544

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Sep 13, 00:30 Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights

Revenue Product Segmentation